Your session is about to expire
← Back to Search
EMB-02 for Cancer
Study Summary
This trial is testing a new cancer drug, EMB-02, to see what dose is safe and how well it works against tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had another cancer within the last 5 years.I am currently taking corticosteroids.You must use very effective birth control methods.I haven't had cancer treatment or radiation in the last 4 weeks.I have not received any live virus vaccines in the last 30 days.I currently have an active infection.I can care for myself and expect to live more than 3 months.My diabetes is not under control, with an A1c over 8%.I have had an organ or bone marrow transplant.I have heart problems.I can provide previous tumor samples or undergo a biopsy.My advanced cancer has not responded to standard treatments and can be measured for changes.I have not had major surgery in the last 4 weeks or minor surgery in the last 2 weeks.You have important health problems that could affect your ability to participate in the study.My organs are functioning well enough for me to join the trial.I have advanced melanoma, not in the eye, treated with specific immunotherapies and my disease can be measured.You have or have had a disease where your immune system attacks your own body.You have experienced severe immune-related side effects from previous treatments.I have recovered from side effects of my previous cancer treatments.I have been treated with a LAG-3 inhibitor before.You have a history of serious allergic reactions.I have symptoms from cancer spread to my brain.You have a history of alcohol, cannabis, or drug abuse.
- Group 1: EMB-02
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are people still able to join this clinical trial?
"Yes, this information is accurate according to the clinicaltrials.gov website. The study was posted on March 11th 2021 and updated as recently as March 28th of this year."
What are we hoping to achieve with this research?
"The primary outcome for this clinical trial, which is set to last an average of 6 months, will be the incidence of DLTs during the first cycle of treatment. Additionally, the sponsor plans to measure secondary outcomes including Steady state volume of distribution (Vss) of EMB-02, Average concentration over a dosing interval (Css, avg)of EMB-02., and Terminal half-life (T1/2) of EMB-02."
Share this study with friends
Copy Link
Messenger